Creo Medical Group plc
("Creo" the "Company" or the
"Group")
Roll-out of
Speedboat® UltraSlim reaches Asia Pacific
The
controlled market release has seen the device used in the UK, USA,
LATAM and now APAC since launch in December 2023
Creo Medical Group
plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces continued
progress on the phased market release of its latest device,
Speedboat® UltraSlim, which has now been successfully used in the
Asia Pacific region ("APAC") for the first time.
Speedboat®
UltraSlim was used at the Prince of Wales Hospital Hong Kong in
late January, where Dr. Hon Chi Yip and Dr. Simon Chu performed
several procedures to treat precancerous lesions in the colon and
stomach.
Since
December 2023 Speedboat® UltraSlim has been successfully used in
multiple clinical applications and in multiple jurisdictions: the
UK, USA, LATAM and now APAC, as well as expanding indications
treating different disease states and conditions. The device has
been used to treat precancerous lesions in the colon, oesophagus
and stomach as well as during procedures to surgically correct
gastric and oesophageal abnormalities to help patients with
swallowing and acid reflux disorders. In all cases these procedures
help move patients from operating theatre procedures to endoscopic
procedures with the inherent reduced impact on the patient and
associated costs.
Dr. Hon Chi Yip, Assistant Professor at the
Division of Upper Gastrointestinal and Metabolic Surgery,
Department of Surgery, Faculty of Medicine, The Chinese University
of Hong Kong said: "The new Speedboat®
UltraSlim allows for use with a broader range of endoscopes,
providing better access and handling. The performance of the
advanced energy has increased the efficiency of the
procedure."
Craig
Gulliford, Chief Executive Officer of Creo Medical, said:
"We're very
pleased that Speedboat® UltraSlim has now reached the Asia Pacific
region, representing tremendous progress with the phased initial
market release in a short period of time. The team have done a
terrific job with the regional regulatory steps necessary to enable
this limited market release programme and we are excited to extend
the roll-out to reach all of our customers in the coming months.
APAC represents the fourth continent where the device has now been
used in clinic and along with Dr. Hon Chi Yip and Dr. Simon Chu, we
have had fantastic feedback from all customers who have so far had
access to the new technology."
Enquiries:
Creo Medical Group plc
|
www.creomedical.com
|
Richard Rees
(CFO)
|
+44 (0)1291 606 005
|
|
|
Cavendish Capital Markets
Limited
|
+44 (0)20 7220 0500
|
Stephen Keys /
Camilla Hume (NOMAD)
|
|
Michael Johnson
(Sales)
|
|
|
|
Deutsche Numis (Joint
Broker)
Freddie Barnfield
/ Duncan Monteith / Euan Brown
|
+44 (0)20 7260 1000
|
|
|
Walbrook PR Ltd
|
Tel: +44 (0)20 7933 8780 or
creo@walbrookpr.com
|
Paul
McManus / Sam Allen /
Phillip
Marriage
|
Mob: +44 (0)7980 541 893 / +44 (0)7502 558
258 / +44
(0)7867 984 082
|
About Creo Medical
Creo is a medical
device company focused on the development and commercialisation of
minimally invasive electrosurgical devices, bringing advanced
energy to endoscopy.
The Company's
vision is to improve patient outcomes through the development and
commercialisation of a suite of electrosurgical medical devices,
each enabled by CROMA, powered by Kamaptive. The Group has
developed the CROMA powered by Kamaptive full-spectrum adaptive
technology to optimise surgical capability and patient outcomes.
Kamaptive is a seamless, intuitive integration of multi-modal
energy sources, optimised to dynamically adapt to patient tissue
during procedures such as resection, dissection, coagulation, and
ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.
CROMA currently delivers bipolar radiofrequency ("RF") energy for
precise localised cutting and focused high frequency microwave
("MW") energy for controlled coagulation and ablation via a single
accessory port. This technology, combined with the Group's range of
patented electrosurgical devices, is designed to provide clinicians
with flexible, accurate and controlled clinical solutions. The
Directors believe the Company's technology can impact the landscape
of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.
For more
information, please refer to the website www.creomedical.com
About Speedboat®
UltraSlim
Speedboat®
UltraSlim is the third device in Creo's Speedboat® family of products, and
is targeting the therapeutic treatment of disease in the GI tract
(including cancer of the Bowel, Stomach and Oesophagus) as well as
surgical procedures to deal with abnormalities resulting in
swallowing disorders and, in some cases, gastric reflux. This
latest generation Speedboat has broad application in the GI tract
due to a smaller configuration, ensuring compatibility with a wide
range of colonoscopes and gastroscopes.
Powered by Creo's
CROMA advanced energy platform, Speedboat® UltraSlim delivers fluid
as well as advanced bipolar RF energy for controlled cutting and
high frequency MW energy for controlled coagulation of tissue in
the GI tract. The device is the culmination of a long
programme of work to further miniaturise Creo's technology, and
is compatible with the
working channel of all commercially available endoscopes accessing
the vast majority of GI endoscopic procedures.